CIRM Funded Clinical Trials

Autologous ARTEMIS® T Cells to Treat Refractory/Relapsed Pediatric Liver Cancer

Disease Area:

Solid Tumors

Investigator:

Institution:

Eureka Therapeutics, Inc.

CIRM Grant:

CLIN2-14338 (Active)

Award Value:

$10,600,072.00

Trial Sponsor:

Eureka Therapeutics, Inc.

Trial Stage:

Phase 1/2

Trial Status:

Launching

Targeted Enrollment:

N/A

Subscribe to Receive CIRM News

Get the latest CIRM news, information on upcoming meetings, and funding opportunities delivered to your inbox.